Evidence map›Paper›PMID 19928931›Full record

ArticleACS nano2009

Multilayered polyelectrolyte films: from active molecular delivery to vaccine therapy.

Jean-Claude Voegel

Abstract readComment
PubMed Publisher
In one paragraph

Article in ACS nano, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Jean-Claude VoegelInstitut National de la Santé et de la Recherche Médicale, 11 rue Humann, Strasbourg, France. jean-claude.voegel@medecine.u-strasbg.fr

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A paper in this issue discusses the use of multilayered polyelectrolyte films incorporating a hydrolytically degradable polymer for transcutaneous drug or vaccine delivery. Dried films could be deconstructed rapidly, and a model protein antigen (ovalbumin) and/or immunostimulatory molecules could be released with different kinetics. Both molecules could also be delivered to antigen-presenting cells in the skin (Langerhans cells). The described approach provides a new route for the storage of vaccines. Successful antigen processing and presentation to lymphocytes remain ongoing challenges before the concept can be used in the next generation of vaccines.

Indexed as

Immunotherapy, ActiveAnimalsCell Line, TumorDrug CarriersElectrolytesHumansMicePolymersTranscription FactorsTumor Necrosis Factor-alphaVaccinesDrug CarriersElectrolytesPolymersTranscription FactorsTumor Necrosis Factor-alphaVaccines

Identifiers

PMID19928931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.